DGAP-News: MeVis Medical Solutions AG / Key word(s): Statement/Offer
MeVis Medical Solutions AG: Joint Reasoned Statement of Executive
Board and Supervisory Board of MeVis Medical Solutions AG
06.02.2015 / 09:30
---------------------------------------------------------------------
Voluntary public takeover offer of VMS Deutschland Holdings GmbH
- Executive and Supervisory Board publish joint statement
- Varian Medical Systems is seen as reliable partner for MeVis'
development
- Recommendation to the shareholders to accept the offer
Bremen, Februar 6, 2015 - Executive Board and Supervisory Board of MeVis
Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical
imaging software, today published a joint statement pursuant to § 27 of the
German Securities Acquisition and Takeover Act (WpÃG) on the voluntary
public takeover offer (cash offer) of VMS Germany Holdings GmbH, Darmstadt,
issued to the shareholders of MeVis Medical Solutions AG on January 27,
2015.
VMS Deutschland Holdings GmbH based in Darmstadt, an affiliate of Varian
Medical Systems, Inc., Palo Alto, California, USA, published a voluntary
public takeover offer on January 27th, 2015 to all shareholders of MeVis
Medical Solutions AG to acquire their registered non-par value shares
against payment of 17.50 Euros per share. The offer is subject to the
condition of a minimum acceptance rate of 75 % of the shares issued by
MeVis Medical Solutions AG (excluding treasury shares).
Varian Medical Systems has become the world's leading manufacturer of
medical devices and software for treating cancer and other diseases through
radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company
supplies software systems for radiation clinics, radiotherapy centers and
medical oncology practices.
Varian is also a premier supplier of X-ray imaging components, including
tubes, digital detectors and image processing software and workstations for
use in medical, scientific and industrial settings, and produces X-ray
systems for cargo screening and industrial inspection applications. Varian
Medical Systems employs approximately 6,800 employees at operating plants
in North America, Europe and China and approximately 75 sales and customer
service centers worldwide.
The publication of the Offer Document by VMS Germany Holdings GmbH and
further information, relevant to the tender offer, is made available in the
internet at http://www.variango1.de.
The Executive Board and Supervisory Board welcome the offer and consider
Varian Medical Systems a reliable partner for the further development of
the MeVis Medical Solutions AG. They regard the offered cash consideration
of 17.50 Euros per share appropriate and are of the opinion that the
transaction is in the interest of MeVis Medical Solutions AG and their
shareholders. The Executive Board and Supervisory Board recommend all MeVis
shareholders to accept the offer.
"Various new sales channels for our existing products will arise with
Varian as a new shareholder, as Varian, in its Imaging Components business,
has already built intensive customer relationships with almost all
important global medical device manufacturers", said Marcus Kirchhoff, CEO
of MeVis Medical Solutions AG. He continued: "The affiliation with Varian
also allows us, in the medium term, the development of other software
products for new market segments."
"Our previously strong dependency on the highly profitable Digital
Mammography Segment has long been a risk for MeVis. Due to the planned
change in the collaboration in medium- and long-term, which was announced
in January 2014, and its associated reduction of business activities with
Hologic, this risk had become more concrete." added Dr. Robert Hannemann,
CFO of MeVis Medical Solutions AG. "With Varian as a new major shareholder
it is expected that this dependency is significantly reduced."
The full text of the joint statement is published in the Internet at
www.mevis.de under Investor Relations/ Aktie/ Ãbernahmeangebot in German
language and is held available free of charge at MeVis Medical Solutions
AG, Investor Relations, Caroline Herschel-Strasse 1, 28359 Bremen, Tel: +49
(0) 421-22495 0 Fax:
+49 (0) 421-22495 499, E-mail: ir@mevis.de.
---------------------------------------------------------------------
06.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
320385 06.02.2015
DGAP-News: MeVis Medical Solutions AG: Joint Reasoned Statement of Executive Board and Supervisory Board of MeVis Medical Solutions AG
| Source: EQS Group AG